Is JCR unlocking the CNS for lysosomal storage diseases before gene therapy gets there?
Find out how JCR Pharmaceuticals is redefining lysosomal disease therapy with brain-targeted delivery platforms.
Is givinostat’s entry into Japan a turning point for DMD care and for JCR Pharmaceuticals’ rare disease strategy?
Find out how Italfarmaco and JCR are bringing the DMD drug givinostat to Japan and what it means for rare disease innovation in Asia.